CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 57,675	$ 313
Costs and expenses
Cost of revenue	245,970	85
Research and development	186,076	167,369
Selling, general and administrative	223,159	131,652
Total cost and expenses	655,205	299,106
Loss from operations	(597,530)	(298,793)
Other income (expense), net:
Change in fair value of forward contracts	0	(442,164)
Interest expense, net	(7,705)	(5)
Other income (expense), net	942	(10)
Total other income (expense), net	516,567	(449,155)
Loss before provision for income taxes	(80,963)	(747,948)
Provision for income taxes	323	4
Net loss	(81,286)	(747,952)
Comprehensive loss	(81,286)	(747,952)
Deemed dividend related to the issuance of Series E convertible preferred stock	0	(2,167,333)
Net loss attributable to common stockholders	$ (81,286)	$ (2,915,285)
Weighted average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)	1,654,322,379	32,650,874
Weighted average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares)	1,654,322,379	32,650,874
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.05)	$ (89.29)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.05)	$ (89.29)
Change in fair value of convertible preferred stock warrant liability
Other income (expense), net:
Change in fair value of stock warrants liability	$ 0	$ (6,976)
Change in fair value of common stock warrant liability
Other income (expense), net:
Change in fair value of stock warrants liability	$ 523,330	$ 0